Can a new pill tame high cholesterol?

NCT ID NCT03381287

Completed Disease control Sponsor: HighTide Therapeutics (Hong Kong) Limited Source: ClinicalTrials.gov ↗

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial evaluates an experimental drug called HTD1801 in overweight or obese adults with high cholesterol. The study aims to see if the drug is safe and tolerable when taken daily at different doses, and how the body processes it. Participants are randomly assigned to receive either HTD1801 or a placebo, and researchers monitor for side effects and measure drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HTD1801 tablets
What this could lead to: If successful, HTD1801 could become a new oral treatment to help manage high cholesterol, potentially reducing the risk of heart disease.
What could go wrong: This is an early-stage trial focused on safety and dosing, not proof of effectiveness. The drug may not lower cholesterol as hoped or may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERCHOLESTEROLEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hypercholesterolemia hyperlipidemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERCHOLESTEROLEMIA

Contacts and locations

Locations

CMAX Clinical Research Pty Ltd

Adelaide, South Australia, 5000, Australia
Linear Clinical Research

Nedlands, Western Australia, 6009, Australia
Q-Pharm Pty Ltd.

Herston, Queensland, 4006, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.